Crucial Deadline Approaches for CureVac Shareholders in BioNTech Takeover Bid

CureVac investors face a pivotal moment as BioNTech’s acquisition proposal moves toward a decisive shareholder vote. The extraordinary general meeting scheduled for November 25 in Amsterdam will determine the fate of this billion-dollar transaction, creating urgency among stockholders who must navigate both timing and tax implications.

BioNTech has presented clear exchange conditions: CureVac shareholders would receive approximately $5.46 in BioNTech American Depositary Shares for each of their current holdings. The tender offer, which commenced on October 22, remains open until December 3, 2025. This valuation places CureVac’s worth at around $1.25 billion, representing a significant strategic move in the competitive landscape of future cancer immunotherapy treatments.

Tax Consequences Create Pressure

Shareholders who Read more...